A team at the University of California, San Diego School of Medicine, backed by the young biotech company Neuralstem, recently launched a clinical trial to assess the safety of neural stem cell transplants in patients one to two years post spinal cord injury.
The Phase I clinical trial is small, recruiting just four volunteers. These patients will have an ASIA-A injury between T2 and T11.
It’s probably too late to have a good shot at participation but as of August 22, the UCSD team is still open to inquiries and is keeping an in-house database for future clinical options.